What is being studied
This catalog lists a combination of cagrilintide and semaglutide. Research on these molecules explores complementary amylin and GLP-1 pathways in metabolic regulation.
RESEARCH PEPTIDE
CagriSema 5 mg
In preparationExplore the listed product information and available batch documentation.
- Product name
- CagriSema
- Listed quantity
- 5 mg
- Composition
- 2.5 mg Cagrilintide + 2.5 mg Semaglutide
- Intended use
- Laboratory research only
- Specifications
- Not yet published
- Availability
- Not available for purchase yet
- Certificate of analysis
- Not yet published
Research reference
Amylin & GLP-1 signaling
A summary of selected literature about the substance. These are not trials of the EVALON product or instructions for use.
Published evidence
REDEFINE clinical trials evaluated specific coadministered formulations in adults with overweight or obesity, including participants with type 2 diabetes.
Limits of the evidence
The catalog mixture is not established as equivalent to the trial formulation or the developer’s CagriSema product. Published outcomes cannot be transferred to this vial.